SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is trending as retail investors and community members speculate on a potential short squeeze, fueled by a high short interest and rumors of a buyout to take the company private. The discourse is further amplified by excitement over new management hires, with many users drawing parallels to past meme stock movements.

Keel Infrastructure Corp. engages in building artificial intelligence focused data centers and energy assets. It focuses on infrastructure and energy required to support high-performance computing and artificial intelligence workloads. The company was founded on April 1, 2026 and is headquartered in New York, NY.

Keel Infrastructure Corp.

Keel Infrastructure Corp

Keel Infrastructure Corp is surging as investors react to analyst optimism regarding the company's AI-ready data center pipeline and its strategic positioning to benefit from growing energy demand. The community is actively debating the timing of potential lease agreements, with bulls pointing to the upcoming Russell 3000 inclusion and government support for nuclear-powered AI infrastructure as key catalysts for sustained long-term growth.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras Systems is facing significant downward pressure as investors rotate out of growth names and express concerns over shrinking margins and potential insider share dilution as the initial lock-up period expires. Despite announcing major long-term infrastructure deals with OpenAI and Amazon Web Services, the market is actively debating the company's valuation multiples and questioning whether its current revenue trajectory can justify its premium market cap.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently experiencing significant downward pressure as market sentiment shifts and high-growth AI stocks face broad technical decompression. While the community remains divided between those viewing the recent price action as a temporary liquidity reset and others bracing for deeper retracement, investor focus remains firmly anchored on whether recent enterprise contract wins can effectively decouple the stock's fundamental growth narrative from current negative price momentum.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community closely monitors a high-stakes legal dispute with Nippon Shinyaku, hoping for a swift resolution that grants Capricor independent control over the distribution of Deramiocel. Investors are simultaneously focused on the upcoming August PDUFA date and anticipation of positive clinical data, viewing the stock as a significant, high-asymmetric opportunity ahead of potential commercialization.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD.com is trending as investors monitor ongoing e-commerce regulatory scrutiny and recent EU expansion probes, while the community remains divided over its long-term viability given the stock's significant underperformance compared to broader market gains. While some participants are actively accumulating shares based on deep-value fundamentals and strong cash positions, many others are expressing frustration over the company's lack of consistent price appreciation and the perceived risks associated with the broader Chinese equity sector.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It operates through the following segments: Uranium, Rare Earth Elements (REE), and Heavy Mineral Sands (HMS). The uranium segment engages in conventional and ISR uranium extraction, recovery and sales of uranium from mineral properties and the recycling of uranium-bearing materials generated by third parties along with the exploration, permitting and evaluation of uranium properties in the U.S. The REE segment is engaged in the company’s initiatives to progress towards full REE separation capabilities at the Mill to produce both light and heavy separated REE oxides in the coming years. The HMS segment engages in the exploration, development and recovery of HMS at the Kwale Project, Bahia Project, Vara Mada Project and the company’s equity method investments in the Donald Project JV and Tate. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels Inc. is trending as investors digest a major $1.9 billion acquisition of German magnet manufacturer VAC, a move that positions the company as the only fully integrated mine-to-magnet rare earth supplier in the Western world. Community discussion is sharply divided, with bulls highlighting the strategic national security importance and government backing, while bears raise concerns about potential dilution and the short-term impact of integrating significant debt.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

The Roundhill Magnificent Seven ETF is attracting intense debate as investors weigh significant capital expenditure cycles against technical signals that suggest potential buy-side exhaustion or a pivotal structural juncture. Community sentiment remains divided between those viewing the basket as a critical flight-to-safety trade and others expressing deep skepticism regarding the sustainability of the underlying AI-focused revenue models.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

iShares Silver Trust is experiencing significant volatility driven by shifting expectations surrounding federal interest rate policy, geopolitical tensions in the Middle East, and ongoing industrial demand. Community discourse is sharply divided between investors betting on a long-term supply deficit in industrial sectors like solar and robotics and those frustrated by the asset's failure to perform as a consistent inflationary hedge.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two Interactive is trending as traders react to leaked information about potential pre-order dates for Grand Theft Auto VI, driving significant anticipation ahead of the company's upcoming earnings report. The community is focused on the game's November release window and the potential for record-breaking engagement to act as a long-term catalyst for the stock.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?

Korro Bio, Inc. (KRRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?

Here is how Amarin (AMRN) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run?

Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals PR Newswire NASHVILLE, Tenn., June 10, 2026 Amneal's Commitment Helps Support a Reliable Supply of Essential...

Amneal and Pfizer GLP-1 Deal: New Growth Lever?

AMRX is expanding into GLP-1 manufacturing and biosimilars, using partnerships and acquisitions to strengthen its higher-value product strategy.

Is Amneal a Buy Before Rytary Generic Erosion?

AMRX faces Rytary generic pressure in 2026, but growth in generics, injectables, biosimilars, and higher profitability targets could support its outlook.

What's Driving Amneal's 2026 Growth Outlook?

AMRX's 2026 outlook is driven by higher profit expectations, a steady launch cadence, and growth from complex generics, injectables, and specialty brands.

Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Amneal Stock Up on FDA Nod for Romidepsin Injection Solution

AMRX gains after FDA approval of ready-to-use romidepsin injection, with 180-day exclusivity and a potential boost to its injectables portfolio.

Is Amneal Pharmaceuticals (AMRX) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

Amneal Pharma Stock Rises On FDA Approval For Generic Version Of AbbVie’s Eyedrops

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

AMRXAmneal Pharmaceuticals Inc - Ordinary Shares - Class A

Fundamentals

Latest AMRX News